Hostname: page-component-7b7567c8c-fvjsw Total loading time: 0 Render date: 2026-11-15T08:29:08.846Z Has data issue: false hasContentIssue false
  • English
  • Français

05-02 The Australian SCAP Study: real-world schizophrenia – economics

Published online by Cambridge University Press:  24 June 2014

W Montgomery,
P Fitzgerald,
AR de Castella,
K Filia,
S Filia,
L Christova and
J Kulkarni
W Montgomery
Affiliation:
Eli Lilly Pty Ltd, Australia
P Fitzgerald
Affiliation:
Alfred Psychiatry Research Centre, The Alfred and Monash University Department of Psychological Medicine, Victoria, Australia
AR de Castella
Affiliation:
Alfred Psychiatry Research Centre, The Alfred and Monash University Department of Psychological Medicine, Victoria, Australia
K Filia
Affiliation:
Alfred Psychiatry Research Centre, The Alfred and Monash University Department of Psychological Medicine, Victoria, Australia
S Filia
Affiliation:
Alfred Psychiatry Research Centre, The Alfred and Monash University Department of Psychological Medicine, Victoria, Australia
L Christova
Affiliation:
M-TAG Australia
J Kulkarni
Affiliation:
Alfred Psychiatry Research Centre, The Alfred and Monash University Department of Psychological Medicine, Victoria, Australia
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

Information

Type
Abstracts from ‘Brainwaves’— The Australasian Society for Psychiatric Research Annual Meeting 2006, 6–8 December, Sydney, Australia
Information
Acta Neuropsychiatrica , Volume 18 , Issue 6 , December 2006, pp. 325
Copyright
Copyright © 2006 Blackwell Munksgaard

Background:

The treatment of patients with schizophrenia consumes a considerable proportion of health service budgets. Despite this, there have been few attempts to prospectively analyze the costs associated with schizophrenia and the relationship of these to clinical outcomes.

Methods:

Direct health care costs were prospectively studied in a cohort of347 patients with schizophrenia in Dandenong, Australia, over 3 years. Indirect costs were estimated from patient's self-reported information.

Results:

The average annual societal cost was A$32 160 per participant in the first year of the study, A$27 190 in the second year and A$29 181 in the third year. Indirect costs accounted for 46% of the total costs in the first year, 52% of the total costs in the second year and 50% of the total costs in the third year. The most expensive component of treatment was in-patient hospital care, which accounted for 42%, 34% and 36% of the total costs in the first, second and third years, respectively.

Conclusions:

Considerable resources are required for the provision of treatment for patients with schizophrenia. However, this expenditure is accompanied by an improvement in clinical outcomes and reported quality of life. The distribution of health care costs is highly skewed, with a relatively small proportion of patients (39%) consuming the majority of resources (80%). An expansion of resources dedicated to supporting a return to employment for this patient group is likely to have substantial benefits in reducing the overall economic and personal impact of this disorder.